GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eculizumab biosimilar overview
Eculizumab biosimilar is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD). It is administered through the intravenous route. It acts by targeting terminal complement protein C5.
Turgut Ilaclari overview
Turgut Ilaclari is a biotechnology company that develop, manufactures and markets pharmaceutical products. It also focused on research and development, product management and sales and technical services. The company focuses to serve human health and also improve the quality by offering high quality generic. It offers products includes GMP biotechnology production facility establishment, global partnerships, academic collaborations and process development. The company is headquartered in Istanbul, Turkey.
For a complete picture of Eculizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.